It is reasonable in DR patients to decrease glucose serum levels with antidiabetic drugs with very low capacity to provoke hypoglycemia, like GLP-1RA and SGLT-2 inhibitors. This evidence concerns the gene SLC5A2 and Hypoglycemia.